Through the agreement Creative Antibiotics AB gains access to Affibody’s two proprietary technology platforms Affibody® molecules and Albumod™. Affibody® molecules are a novel class of antibody mimetics that have excellent efficacy, safety, and administration route benefits. Albumod™ is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life.
The agreement consists of a defined protein target development collaboration and a product license agreement. Creative Antibiotics will be responsible for the future development of the products.
About Affibody
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.
For more information please refer to: www.affibody.se.
About Creative Antibiotics
Creative Antibiotics was founded in 2000 to commercialize cutting edge research at the Umeå University, Sweden, and the Karolinska Institute in Stockholm, Sweden.
The company has developed and patented a number of substances against bacterial infections, so called virulence blockers. The substances block the capabilities of certain bacteria to cause disease without eliminating them. If bacteria are disarmed rather than being eliminated, the risk that the bacteria develop resistance towards the drug decreases.
For more information please refer to: www.creativeantibiotics.se.